A Biomarker Study of Tivozanib in Subjects With Advanced Renal Cell Carcinoma
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm, multicenter study. Subjects will be stratified by
histology (clear cell versus non-clear cell). Enrollment of non-clear cell subjects will be
limited to ≤ 30% of the entire study population.